-
1
-
-
33746336252
-
Thalidomide and lenalidomide in the treatment of multiple myeloma
-
DOI 10.1016/j.ejca.2006.04.004, PII S095980490600308X
-
Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006;42:1612-22. (Pubitemid 44118763)
-
(2006)
European Journal of Cancer
, vol.42
, Issue.11
, pp. 1612-1622
-
-
Kumar, S.1
Rajkumar, S.V.2
-
2
-
-
2142825614
-
Thalidomide: An old drug with new clinical applications
-
DOI 10.1517/14740338.3.1.47
-
Laffite E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf. 2004;3(1):47-56. (Pubitemid 38765186)
-
(2004)
Expert Opinion on Drug Safety
, vol.3
, Issue.1
, pp. 47-56
-
-
Laffitte, E.1
Revuz, J.2
-
3
-
-
61349118005
-
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
-
18774632 10.1016/j.blre.2008.07.003 1:CAS:528:DC%2BD1MXmtlWltLo%3D
-
Palumbo A, Dimopoulos M, San Miguel J, et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev. 2009;23:87-93.
-
(2009)
Blood Rev
, vol.23
, pp. 87-93
-
-
Palumbo, A.1
Dimopoulos, M.2
San Miguel, J.3
-
4
-
-
0036381106
-
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells
-
12296856 10.1046/j.1365-2249.2002.01954.x 1:CAS:528:DC%2BD38XotlGgsr0%3D
-
Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol. 2002;130:75-84.
-
(2002)
Clin Exp Immunol
, vol.130
, pp. 75-84
-
-
Marriott, J.B.1
Clarke, I.A.2
Dredge, K.3
Muller, G.4
Stirling, D.5
Dalgleish, A.G.6
-
5
-
-
0036839013
-
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
-
DOI 10.1182/blood-2002-03-0996
-
Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100(9):3063-7. (Pubitemid 35217050)
-
(2002)
Blood
, vol.100
, Issue.9
, pp. 3063-3067
-
-
Richardson, P.G.1
Schlossman, R.L.2
Weller, E.3
Hideshima, T.4
Mitsiades, C.5
Davies, F.6
Leblanc, R.7
Catley, L.P.8
Doss, D.9
Kelly, K.10
McKenney, M.11
Mechlowicz, J.12
Freeman, A.13
Deocampo, R.14
Rich, R.15
Ryoo, J.J.16
Chauhan, D.17
Balinski, K.18
Zeldis, J.19
Anderson, K.C.20
more..
-
6
-
-
33750607347
-
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
-
16840727 10.1182/blood-2006-04-015909 1:CAS:528:DC%2BD28Xht1ahsLzO
-
Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108(10):3458-64.
-
(2006)
Blood
, vol.108
, Issue.10
, pp. 3458-3464
-
-
Richardson, P.G.1
Blood, E.2
Mitsiades, C.S.3
-
7
-
-
36349010285
-
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
-
DOI 10.1056/NEJMoa070596
-
Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New Engl J Med. 2007;357(21):2133-42. (Pubitemid 350146108)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.21
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
Wang, M.4
Belch, A.5
Stadtmauer, E.A.6
Siegel, D.7
Borrello, I.8
Rajkumar, S.V.9
Chanan-Khan, A.A.10
Lonial, S.11
Yu, Z.12
Patin, J.13
Olesnyckyj, M.14
Zeldis, J.B.15
Knight, R.D.16
-
8
-
-
36349023319
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
DOI 10.1056/NEJMoa070594
-
Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone versus dexamethasone alone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-32. (Pubitemid 350146107)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.21
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
Prince, H.M.4
Harousseau, J.-L.5
Dmoszynska, A.6
San Miguel, J.7
Hellmann, A.8
Facon, T.9
Foa, R.10
Corso, A.11
Masliak, Z.12
Olesnyckyj, M.13
Yu, Z.14
Patin, J.15
Zeldis, J.B.16
Knight, R.D.17
-
9
-
-
33845590841
-
Pharmacovigilance for evaluating adverse drug reactions: Value, organization, and methods
-
DOI 10.1016/j.jbspin.2006.09.002, PII S1297319X0600217X
-
Montastruc JL, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine. 2006;73(6):629-32. (Pubitemid 44932244)
-
(2006)
Joint Bone Spine
, vol.73
, Issue.6
, pp. 629-632
-
-
Montastruc, J.-L.1
Sommet, A.2
Lacroix, I.3
Olivier, P.4
Durrieu, G.5
Damase-Michel, C.6
Lapeyre-Mestre, M.7
Bagheri, H.8
-
10
-
-
0034619028
-
Adverse drug reactions: Definitions, diagnosis and management
-
11072960 10.1016/S0140-6736(00)02799-9 1:CAS:528:DC%2BD3cXot1agsr8%3D
-
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000;356(9237):1255-9.
-
(2000)
Lancet
, vol.356
, Issue.9237
, pp. 1255-1259
-
-
Edwards, I.R.1
Aronson, J.K.2
-
11
-
-
0032991290
-
The Medical Dictionary for Regulatory Activities (MedDRA)
-
DOI 10.2165/00002018-199920020-00002
-
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109-17. (Pubitemid 29101275)
-
(1999)
Drug Safety
, vol.20
, Issue.2
, pp. 109-117
-
-
Brown, E.G.1
Wood, L.2
Wood, S.3
-
12
-
-
0022036232
-
Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France
-
Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie. 1985;40(2):111-8.
-
(1985)
Thérapie
, vol.40
, Issue.2
, pp. 111-118
-
-
Bégaud, B.1
Evreux, J.C.2
Jouglard, J.3
Lagier, G.4
-
13
-
-
78649707335
-
Lenalidomide mode of action: Linking bench and clinical findings
-
21126632 10.1016/S0268-960X(10)70004-7
-
Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24(Suppl 1):S13-9.
-
(2010)
Blood Rev
, vol.24
, Issue.SUPPL. 1
-
-
Davies, F.1
Baz, R.2
-
14
-
-
23644450583
-
Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001)
-
DOI 10.2165/00002018-200528080-00007
-
Thiessard F, Roux E, Miremont-Salame G, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Drug Saf. 2005;28(8):731-40. (Pubitemid 41132459)
-
(2005)
Drug Safety
, vol.28
, Issue.8
, pp. 731-740
-
-
Thiessard, F.1
Roux, E.2
Miremont-Salame, G.3
Fourrier-Reglat, A.4
Haramburu, F.5
Tubert-Bitter, P.6
Begaud, B.7
-
15
-
-
33646744337
-
Under-reporting of adverse drug reactions: A systematic review
-
16689555 10.2165/00002018-200629050-00003
-
Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-96.
-
(2006)
Drug Saf
, vol.29
, Issue.5
, pp. 385-396
-
-
Hazell, L.1
Shakir, S.A.2
-
16
-
-
0030826946
-
Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union
-
DOI 10.1007/s002280050314
-
Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union: the European Pharmacovigilance Research Group. Eur J Clin Pharmacol. 1997;52(6):423-7. (Pubitemid 27395640)
-
(1997)
European Journal of Clinical Pharmacology
, vol.52
, Issue.6
, pp. 423-427
-
-
Belton, K.J.1
Gram, L.F.2
Royer, R.J.3
Feely, J.4
McGettigan, P.5
Velo, G.P.6
Conforti, A.7
Leone, R.8
Stricker, B.H.Ch.9
Teixeira, F.10
Laporte, J.R.11
Capella, D.12
Beermann, B.13
Belton, K.J.14
Lewis, S.C.15
Payne, S.16
Rawlins, M.D.17
Wood, S.M.18
-
17
-
-
84870699940
-
Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?
-
22961933 10.1002/pds.3333
-
Paludetto MN, Olivier-Abbal P, Montastruc JL. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France? Pharmacoepidemiol Drug Saf. 2012;21(12):1289-94.
-
(2012)
Pharmacoepidemiol Drug Saf
, vol.21
, Issue.12
, pp. 1289-1294
-
-
Paludetto, M.N.1
Olivier-Abbal, P.2
Montastruc, J.L.3
-
18
-
-
0002656565
-
Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs
-
K.D. Rainsford G. Velo (eds) 6 Raven Press New York
-
Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in inflammation research, vol. 6. New York: Raven Press; 1984. p. 1-6.
-
(1984)
Advances in Inflammation Research
, pp. 1-6
-
-
Weber, J.C.P.1
-
19
-
-
77949890246
-
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: A comparative analysis of 411 patients
-
20008302 10.1182/blood-2009-08-239046 1:CAS:528:DC%2BC3cXjtVWruro%3D
-
Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115(7):1343-50.
-
(2010)
Blood
, vol.115
, Issue.7
, pp. 1343-1350
-
-
Gay, F.1
Hayman, S.R.2
Lacy, M.Q.3
-
20
-
-
77956928323
-
Multiple myeloma: Management of adverse events
-
19582597 10.1007/s12032-009-9262-4 1:STN:280:DC%2BC3cjmtVWlsg%3D%3D
-
Gay F, Palumbo A. Multiple myeloma: management of adverse events. Med Oncol. 2010;27(3):646-53.
-
(2010)
Med Oncol
, vol.27
, Issue.3
, pp. 646-653
-
-
Gay, F.1
Palumbo, A.2
-
22
-
-
77952817334
-
Management of treatment-related adverse events in patients with multiple myeloma
-
20472185 10.1016/S0305-7372(10)70009-8
-
Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010;36(Suppl 2):S24-32.
-
(2010)
Cancer Treat Rev
, vol.36
, Issue.SUPPL. 2
-
-
Mateos, M.V.1
-
23
-
-
79955646392
-
Lenalidomide treatment for patients with multiple myeloma: Diagnosis and management of most frequent adverse events
-
Pérez Persona E, Mesa MG, García Sánchez PJ, González Rodríguez AP. Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. Adv Ther. 2011;28(Suppl 1):11-6.
-
(2011)
Adv Ther
, vol.28
, Issue.SUPPL. 1
, pp. 11-16
-
-
Pérez Persona E, M.1
-
24
-
-
34548138921
-
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
-
DOI 10.1038/sj.leu.2404801, PII 2404801
-
Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):2035-42. (Pubitemid 47299979)
-
(2007)
Leukemia
, vol.21
, Issue.9
, pp. 2035-2042
-
-
Kumar, S.1
Dispenzieri, A.2
Lacy, M.Q.3
Hayman, S.R.4
Buadi, F.K.5
Gastineau, D.A.6
Litzow, M.R.7
Fonseca, R.8
Roy, V.9
Rajkumar, S.V.10
Gertz, M.A.11
-
25
-
-
77449111211
-
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia
-
19965623 10.1182/blood-2009-05-221077 1:CAS:528:DC%2BC3cXhsFegsLY%3D
-
Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010;115(3):605-14.
-
(2010)
Blood
, vol.115
, Issue.3
, pp. 605-614
-
-
Pal, R.1
Monaghan, S.A.2
Hassett, A.C.3
-
26
-
-
77954086364
-
Management of disease- and treatment-related complications in patients with multiple myeloma
-
20467920 10.1007/s12032-010-9542-z 1:CAS:528:DC%2BC3cXnsFylsr0%3D
-
Gay F, Palumbo A. Management of disease- and treatment-related complications in patients with multiple myeloma. Med Oncol. 2010;27:S43-52.
-
(2010)
Med Oncol
, vol.27
-
-
Gay, F.1
Palumbo, A.2
-
27
-
-
55449104900
-
Images in HIV/AIDS. Stevens-Johnson syndrome associated with thalidomide treatment in HIV infection
-
18975442
-
Tebruegge M, Pantazidou A. Images in HIV/AIDS. Stevens-Johnson syndrome associated with thalidomide treatment in HIV infection. AIDS Read. 2008;18(10):519-20.
-
(2008)
AIDS Read
, vol.18
, Issue.10
, pp. 519-520
-
-
Tebruegge, M.1
Pantazidou, A.2
-
28
-
-
67349247571
-
Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy
-
19052692 10.1007/s12185-008-0220-2
-
Colagrande M, Di Ianni M, Coletti G, et al. Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. Int J Hematol. 2009;89(1):76-9.
-
(2009)
Int J Hematol
, vol.89
, Issue.1
, pp. 76-79
-
-
Colagrande, M.1
Di Ianni, M.2
Coletti, G.3
-
29
-
-
77649281023
-
Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: A case report
-
19693501 10.1007/s00277-009-0810-y
-
Eo WK, Kim SH, Cheon SH, et al. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report. Ann Hematol. 2010;89(4):421-2.
-
(2010)
Ann Hematol
, vol.89
, Issue.4
, pp. 421-422
-
-
Eo, W.K.1
Kim, S.H.2
Cheon, S.H.3
-
30
-
-
0032858116
-
Thalidomide-induced toxic epidermal necrolysis
-
DOI 10.1592/phco.19.15.1177.30571
-
Horowitz SB, Stirling AL. Thalidomide-induced toxic epidermal necrolysis. Pharmacotherapy. 1999;19(10):1177-80. (Pubitemid 29455940)
-
(1999)
Pharmacotherapy
, vol.19
, Issue.10
, pp. 1177-1180
-
-
Horowitz, S.B.1
Stirling, A.L.2
-
31
-
-
0034727058
-
Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
-
11012329 10.1056/NEJM200009283431315 1:STN:280:DC%2BD3cvmtVSisA%3D%3D
-
Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med. 2000;343(13):972-3.
-
(2000)
N Engl J Med
, vol.343
, Issue.13
, pp. 972-973
-
-
Rajkumar, S.V.1
Gertz, M.A.2
Witzig, T.E.3
-
32
-
-
58149343983
-
Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients
-
19047275 10.1200/JCO.2008.20.3737
-
Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol. 2009;27(1):156-7.
-
(2009)
J Clin Oncol
, vol.27
, Issue.1
, pp. 156-157
-
-
Castaneda, C.P.1
Brandenburg, N.A.2
Bwire, R.3
Burton, G.H.4
Zeldis, J.B.5
-
33
-
-
0034745883
-
Thalomid (Thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing
-
11235821 10.2165/00002018-200124020-00002 1:CAS:528:DC%2BD3MXhs1Whu7w%3D
-
Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf. 2001;24(2):87-117.
-
(2001)
Drug Saf
, vol.24
, Issue.2
, pp. 87-117
-
-
Clark, T.E.1
Edom, N.2
Larson, J.3
Lindsey, L.J.4
-
34
-
-
78649715070
-
Lenalidomide: An update on evidence from clinical trials
-
21126633 10.1016/S0268-960X(10)70005-9
-
Dimopoulos MA, Terpos E. Lenalidomide: an update on evidence from clinical trials. Blood Rev. 2010;24(Suppl 1):S21-6.
-
(2010)
Blood Rev
, vol.24
, Issue.SUPPL. 1
-
-
Dimopoulos, M.A.1
Terpos, E.2
-
35
-
-
33646494190
-
Lenalidomide and venous thrombosis in multiple myeloma
-
16696148 10.1056/NEJMc053530
-
Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354(19):2079-80.
-
(2006)
N Engl J Med
, vol.354
, Issue.19
, pp. 2079-2080
-
-
Rajkumar, S.V.1
Blood, E.2
-
36
-
-
44449135859
-
Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers
-
10.1016/j.patbio.2008.02.013 1:STN:280:DC%2BD1cvitlCktw%3D%3D
-
Drouet L. Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers. Pathol Biol (Paris). 2008;56(4):195-204.
-
(2008)
Pathol Biol (Paris)
, vol.56
, Issue.4
, pp. 195-204
-
-
Drouet, L.1
-
37
-
-
76549137222
-
Peripheral neuropathy and new treatments for multiple myeloma: Background and practical recommendations
-
20139393 10.3324/haematol.2009.012674 1:CAS:528:DC%2BC3cXht1yjtr%2FK
-
Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311-9.
-
(2010)
Haematologica
, vol.95
, Issue.2
, pp. 311-319
-
-
Mohty, B.1
El-Cheikh, J.2
Yakoub-Agha, I.3
Moreau, P.4
Harousseau, J.L.5
Mohty, M.6
-
38
-
-
78049528177
-
Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues
-
20932799 10.1016/S1470-2045(10)70068-1 1:CAS:528:DC%2BC3cXhtlKmtrnF
-
Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086-95.
-
(2010)
Lancet Oncol
, vol.11
, Issue.11
, pp. 1086-1095
-
-
Delforge, M.1
Bladé, J.2
Dimopoulos, M.A.3
-
39
-
-
79958007072
-
Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?
-
21497966 10.1016/j.blre.2011.03.005 1:CAS:528:DC%2BC3MXntVeltr0%3D
-
Palumbo A, Mateos MV, Bringhen S, San Miguel JF. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev. 2011;25(4):181-91.
-
(2011)
Blood Rev
, vol.25
, Issue.4
, pp. 181-191
-
-
Palumbo, A.1
Mateos, M.V.2
Bringhen, S.3
San Miguel, J.F.4
-
40
-
-
33749051832
-
Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
-
DOI 10.1200/JCO.2006.05.6689
-
Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patters of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24(27):4507-14. (Pubitemid 46630990)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.27
, pp. 4507-4514
-
-
Mileshkin, L.1
Stark, R.2
Day, B.3
Seymour, J.F.4
Zeldis, J.B.5
Prince, H.M.6
-
41
-
-
84860709392
-
Lenalidomide maintenance after stemcell transplantation for multiple myeloma
-
22571202 10.1056/NEJMoa1114138 1:CAS:528:DC%2BC38Xnt1Gjsrs%3D
-
Attal M, Lauwers VC, Marit G, et al. Lenalidomide maintenance after stemcell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91.
-
(2012)
N Engl J Med
, vol.366
, Issue.19
, pp. 1782-1791
-
-
Attal, M.1
Lauwers, V.C.2
Marit, G.3
-
42
-
-
84860741191
-
Lenalidomide after stem-cell transplantation for multiple myeloma
-
22571201 10.1056/NEJMoa1114083 1:CAS:528:DC%2BC38Xnt1Gjsro%3D
-
McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
-
(2012)
N Engl J Med
, vol.366
, Issue.19
, pp. 1770-1781
-
-
McCarthy, P.L.1
Owzar, K.2
Hofmeister, C.C.3
-
43
-
-
84860744403
-
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
-
22571200 10.1056/NEJMoa1112704 1:CAS:528:DC%2BC38Xnt1Gjsrw%3D
-
Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
-
(2012)
N Engl J Med
, vol.366
, Issue.19
, pp. 1759-1769
-
-
Palumbo, A.1
Hajek, R.2
Delforge, M.3
-
44
-
-
84858824788
-
Second malignancies after multiple myeloma: From 1960s to 2010s
-
22310913 10.1182/blood-2011-12-381426 1:CAS:528:DC%2BC38XkvFalt7g%3D
-
Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012;119(12):2731-7.
-
(2012)
Blood
, vol.119
, Issue.12
, pp. 2731-2737
-
-
Thomas, A.1
Mailankody, S.2
Korde, N.3
Kristinsson, S.Y.4
Turesson, I.5
Landgren, O.6
-
45
-
-
84891887368
-
-
European Medicines Agency. Revlimid: EPAR (European Public Assessment Report)-Scientific discussion (26/6/2007) Accessed April 4, 2013
-
European Medicines Agency. Revlimid: EPAR (European Public Assessment Report)-Scientific discussion (26/6/2007) http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific-Discussion/human/000717/WC500056022.pdf. Accessed April 4, 2013.
-
-
-
|